FORT LAUDERDALE, Fla. — Aflibercept 8 mg demonstrated sustained functional and anatomic improvements in patients with wet age-related macular degeneration through 156 weeks, according to a presenter.
At the Retina World Congress, David T. Wong, MD, FRCSC, DRCPSC, presented results from the PULSAR extension study, which builds on the initial PULSAR study investigating aflibercept 2 mg dosed every 8 weeks (336 patients), aflibercept 8 mg dosed every 12 weeks (335 patients) and aflibercept 8 mg dosed every 16 weeks (338 patients), all after three initial monthly injections. At 96 weeks (Read more...)